Login
$CGTX
$0.65 +$0.01 (1.75%) After hours

$CGTX 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition; Notice of Delisting or Failure to Satisfy a Listing Rule

Purchase, NY – November 5, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results...

22 Oct 2026 8-K: Other Events

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

06 Aug 2026 8-K: Results of Operations and Financial Condition

Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results f...

24 Jun 2026 8-K: Other Events

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Cognition Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting resul...

04 Jun 2026 8-K: Regulation FD Disclosure

https://cogrx.com COGNITION THERAPEUTICS · NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 · Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis

21 May 2026 8-K: Other Events

- Positive Discussion on Path Forward for Registrational Program -

07 May 2026 8-K: Results of Operations and Financial Condition

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis

26 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

March 2026 Zervimesine: a Once-daily Oral Therapeutic Advancing Toward Phase 3

02 Mar 2026 8-K: Other Events

- Regulatory strategy expedites development of potential first treatment to address DLB psychosis -

27 Jan 2026 8-K: Other Events

PURCHASE, NY – January 27, 2026 – Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food an...

18 Dec 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

On December 18, 2025, Cognition Therapeutics, Inc. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may sell, from time to time, at its o...

06 Nov 2025 8-K: Results of Operations and Financial Condition

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

15 Sep 2025 8-K: Other Events

September 2025 Zervimesine: a Once-daily Oral Therapeutic Advancing Towards Phase 3

28 Aug 2025 8-K: Entry into a Material Definitive Agreement

This Securities Purchase Agreement (this “Agreement”) is dated as of August 27, 2025, between Cognition Therapeutics, Inc., a company incorporated under the laws of Delaware (the “Company”), and each purchaser identified on the signature...

26 Aug 2025 8-K: Other Events

As previously disclosed, on September 12, 2024, Cognition Therapeutics, Inc. (the “Company”) received a deficiency letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the bid price of its common stock had closed below the $1....

07 Aug 2025 8-K: Results of Operations and Financial Condition

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

20 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2025, Cognition Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting resul...

03 Jun 2025 8-K: Other Events

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

02 Jun 2025 8-K: Other Events

Targeting Pathogenic Oligomers: June 2025 A Disruptive Approach to the Treatment of Neurodegenerative Diseases

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support